The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for ARK Diagnostics sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights ARK Diagnostics Inc, United States Revenue

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

ARK Diagnostics is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company’s products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lamotrigine assay, fentanyl assay, zonisamide assay, methotrexate assay, thyroxine assay, and entry inhibitor. Its products are used in the therapeutic areas of epilepsy, pain management, cancer, urine test, veterinary, and HIV or AIDS. ARK Diagnostics’ protease inhibitors include ritonavir, darunavir, saquinavir, amprenavir, lopinavir, atazanavir, indinavir and tipranavir. The company’s immunoassays measure drug levels in biological fluids that enable clinicians to guide dosing decisions for drug therapy. It distributes its products across Germany, Austria, Belgium, the Netherlands, Luxembourg, the UK and Ireland. ARK Diagnostics is headquartered in Fremont, California, the US.

The key metrics of ARK Diagnostics related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As ARK Diagnostics is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as ARK Diagnostics.

For a detailed understanding of the performance of ARK Diagnostics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.